EchoGo® Heart Failure vs vascuCAP
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These two FDA-cleared AI tools offer adjacent capabilities in cardiovascular clinical decision support, but utilize different imaging modalities and address distinct diagnostic needs. EchoGo® Heart Failure is designed for detecting HFpEF through echocardiogram analysis, providing rapid insights for heart failure diagnosis. In contrast, vascuCAP focuses on quantifying plaque composition from CT angiograms to assess broader cardiovascular risk for conditions like stroke and heart attack.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Heart Failure is an AI platform that analyzes routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF), providing insights within 20 minutes to support clinical decisions. vascuCAP (now ElucidVivo/PlaqueIQ) is an AI software for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk to optimize treatment decisions for conditions like stroke and heart attack.
EchoGou00ae Heart Failure analyzes routine echocardiogram video clips, specifically a single apical 4-chamber view. vascuCAP (ElucidVivo/PlaqueIQ) processes non-invasive CT angiography for its analysis, and can also process MRI.
EchoGou00ae Heart Failure provides AI-powered HFpEF detection with reported 90% sensitivity and 86% specificity, delivering insights within 20 minutes through automated structured reports. vascuCAP (ElucidVivo/PlaqueIQ) quantifies plaque components such as lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage, offering 3D visualization and risk stratification for stroke and heart attack.
Both tools offer DICOM integration for report delivery to PACS and interoperability with EMRs. EchoGou00ae Heart Failure is a cloud-deployed solution designed for seamless integration, while vascuCAP (ElucidVivo/PlaqueIQ) provides both cloud and on-premise secure deployment options.
EchoGou00ae Heart Failure is clinically validated with 90% sensitivity and 86% specificity for HFpEF detection, and was trained on over 10 years of outcome data. vascuCAP (ElucidVivo/PlaqueIQ) features histologically-validated plaque quantification and characterization, with its algorithms validated by expert pathologists using tissue specimens as an objective truth standard.